Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
about
Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?The PETALE study: Late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors.
P2860
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
@en
type
label
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
@en
prefLabel
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
@en
P2093
P2860
P1476
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
@en
P2093
Caroline Laverdière
Maja Krajinovic
Stéphanie Dulucq
P2860
P304
P356
10.1517/17425255.2014.893294
P407
P577
2014-03-27T00:00:00Z